250 related articles for article (PubMed ID: 8667046)
1. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
3. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
4. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
[TBL] [Abstract][Full Text] [Related]
5. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.
Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Zanzi I; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1994 Jun; 35(6):955-63. PubMed ID: 8195882
[TBL] [Abstract][Full Text] [Related]
6. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Wahl L; Nahmias C
J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
[TBL] [Abstract][Full Text] [Related]
7. Striatal kinetic modeling of FDOPA with a cerebellar-derived constraint on the distribution of volume of 30MFD: a PET investigation using non-human primates.
Shoghi-Jadid K; Huang SC; Stout DB; Yee RE; Yeh EL; Farahani KF; Satyamurthy N; Phelps ME; Barrio JR
J Cereb Blood Flow Metab; 2000 Jul; 20(7):1134-48. PubMed ID: 10908046
[TBL] [Abstract][Full Text] [Related]
8. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
9. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
10. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
11. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
12. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
15. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.
Vernaleken I; Kumakura Y; Cumming P; Buchholz HG; Siessmeier T; Stoeter P; Müller MJ; Bartenstein P; Gründer G
Neuroimage; 2006 May; 30(4):1332-9. PubMed ID: 16439159
[TBL] [Abstract][Full Text] [Related]
16. Striatal 18F-dopa uptake: absence of an aging effect.
Eidelberg D; Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Margouleff D; Moeller JR; Patlak CS; Fahn S
J Cereb Blood Flow Metab; 1993 Sep; 13(5):881-8. PubMed ID: 8360294
[TBL] [Abstract][Full Text] [Related]
17. Automated striatal uptake analysis of ¹⁸F-FDOPA PET images applied to Parkinson's disease patients.
Chang IC; Lue KH; Hsieh HJ; Liu SH; Kao CH
Ann Nucl Med; 2011 Dec; 25(10):796-803. PubMed ID: 21887536
[TBL] [Abstract][Full Text] [Related]
18. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
[TBL] [Abstract][Full Text] [Related]
19. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
[TBL] [Abstract][Full Text] [Related]
20. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
